Clinical Research Directory
Browse clinical research sites, groups, and studies.
6 clinical studies listed.
Filters:
Tundra lists 6 Motion Sickness clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07297862
Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients
The aim of this study is to examine the effects of virtual reality on physiological factors (heart rate, blood pressure) in stroke patients and the psychometric properties of the Virtual Reality Sickness Questionnaire in assessing Motion Sickness resulting from virtual reality use.
Gender: All
Ages: 18 Years - 80 Years
Updated: 2026-03-25
NCT06106256
Three-Axis Wearable Adaptive Vestibular Stimulator
The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2026-01-30
1 state
NCT06138613
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Gender: All
Ages: 18 Years - 75 Years
Updated: 2025-11-21
1 state
NCT05622344
StableEyes With Active Neurofeedback
The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.
Gender: All
Ages: 21 Years - 70 Years
Updated: 2025-11-10
2 states
NCT06892340
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
The purpose of this research study is to learn how a wearable nerve stimulation device, the Spark Biomedical's Sparrow Ascent System™, impacts the development of spatial disorientation and/or motion sickness in a healthy population. Spatial disorientation is when there is a "mismatch" between where a person is, and where the sense organs in their body tell them where they are. These sense organs include the inner ear (the vestibular system), the eyes (the visual system), the sense of where one's legs, back, and neck are (proprioceptive system), and one's higher thinking (cognitive centers). If spatial disorientation is severe or occurs in motion-naïve individuals, spatial disorientation can lead to motion sickness. The Sparrow Ascent System™ is a wearable, battery-operated transcutaneous auricular (ear) neurostimulation (tAN) device. This means that it uses electrical pulses to stimulate branches of nerves on and/or around the ear, specifically the "vagus" and "trigeminal" nerves. These nerves are also responsible for your sensation of nausea and your heart rate (vagus nerve), as well as headaches (trigeminal nerve). The Sparrow System utilizes a flexible earpiece with embedded hydrogel electrodes that stick to the skin, the earpiece is disposable after use. This device is already Food and Drug Administration (FDA) approved for use in humans and is safely used for control of symptoms in a variety of other medical conditions, such as opioid withdrawal and acute stress reaction. In this study, we will determine if the Sparrow Ascent System™ impacts the development of spatial disorientation or motion sickness.
Gender: All
Ages: 18 Years - 50 Years
Updated: 2025-08-15
1 state
NCT05886660
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).
Gender: All
Ages: 18 Years - 65 Years
Updated: 2024-05-17
1 state